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A Human mAb Specific to Oncofetal Fibronectin
Selectively Targets Chronic Skin Inflammation in vivo
Eveline Trachsel1, Manuela Kaspar1, Frank Bootz1, Michael Detmar1 and Dario Neri1
The antibody-based targeted delivery of bioactive agents to sites of angiogenesis is an attractive therapeutic
strategy for cancer treatment, but is largely unexplored for chronic inflammatory diseases. In this article, we
show that the extra domain B (EDB) domain of fibronectin, a marker of angiogenesis, is expressed in psoriatic
lesions, and that the anti-EDB human antibody L19 can selectively localize to chronically inflamed skin in vivo.
The L19-based delivery of the cytokines IL10 and IL12 did not improve or worsen inflammation in a mouse
model of chronic skin inflammation, which overexpressed vascular endothelial growth factor under the control
of the keratin-14 promoter. By contrast, the L19-based targeted delivery of the proinflammatory cytokine IL2 or
of the photosensitizer Sn(IV) chlorin e6 resulted in an increased swelling and reddening of inflamed skin. These
results indicate that antibodies specific to components of the modified extracellular matrix can selectively
accumulate at chronically inflamed sites in vivo. This observation now stimulates the search for bioactive
molecules which can be fused to antibodies and which may confer a therapeutic benefit as a result of their
preferential accumulation in psoriatic lesions and other sites of inflammation.
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INTRODUCTION
The exquisite specificity of antigen recognition by mono-
clonal antibodies is becoming increasingly used for the
targeted delivery of active molecules to sites of disease for
therapeutic applications and for imaging (Verel et al., 2005;
Wu and Senter, 2005). In oncology, therapeutic benefits have
been observed both with Igs in IgG format (which, by virtue
of their constant region, can activate complement and engage
with Fc receptors on leukocytes), and with antibody
derivatives, such as radiolabeled antibodies (Borjesson
et al., 2004; Brack et al., 2004), drug conjugates (Hamblett
et al., 2004; Smith, 2005), and antibody-cytokine fusion
proteins (Carnemolla et al., 2002; Halin et al., 2002; Borsi
et al., 2003; Ebbinghaus et al., 2005; Gafner et al., 2006). In
particular, the selective delivery of antibodies to accessible
antigens expressed around newly formed blood vessels
(‘‘vascular targeting’’) is often associated with an improved
targeting performance (Neri and Bicknell, 2005; Trachsel and
Neri, 2006) and may allow certain biomolecular therapeutic
strategies which are only possible in close proximity of
vascular structures. For example, the antibody-based targeted
delivery of photosensitizers to tumor blood vessels, followed
by irradiation, mediates a rapid intraluminal blood coagula-
tion triggering tumor cell death (Fabbrini et al., 2006).
In principle, vascular targeting applications are not limited
to cancer. Our group has previously demonstrated the use of
monoclonal antibodies for the targeted delivery of fluoro-
phores and photosensitizers to new blood vessels in a rabbit
model of ocular angiogenesis (Birchler et al., 1999) and to
vasa vasorum in atherosclerotic plaques in ApoE/ mice,
fed with a cholesterol-rich diet (Matter et al., 2004). Both sets
of experiments were performed using derivatives of the
human antibody L19 (Pini et al., 1998), specific to the extra
domain B (EDB) of fibronectin, a marker of angiogenesis
(Zardi et al., 1987; Castellani et al., 1994; Carnemolla et al.,
1996; Castellani et al., 2002; Neri and Bicknell, 2005).
EDB is a small domain of 91 amino acids, which can be
inserted in the fibronectin molecules by a mechanism of
alternative splicing (Zardi et al., 1987). The sequence of EDB
is identical in mouse and man (Fattorusso et al., 1999), thus
permitting the characterization of the target in immunocom-
petent animal models of pathology. EDB is overexpressed
during embryonic development and in a variety of solid
tumors but is virtually undetectable in normal adult tissues,
except for the endometrium in the proliferative phase and
some vessels in the ovaries (Castellani et al., 2002). Psoriasis
is a chronic inflammatory skin disease that is associated with
prominent involvement of angiogenesis (Bayliffe et al., 2004;
Nickoloff and Nestle, 2004) in early plaque development
(Christophers et al., 1973) as well as in fully developed
lesions (Braverman and Keh-Yen, 1986). There is emerging
evidence for a pathogenic role for vascular endothelial
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growth factor (VEGF) in psoriasis (Xia et al., 2003; Young
et al., 2004). To our knowledge, there are no reports on EDB
expression in psoriasis.
In this study, we investigated the expression of EDB in
both human psoriatic skin and in a mouse model of chronic
skin inflammation, based on the overexpression of VEGF-A
under the control of the keratin-14 promoter (Xia et al., 2003;
Kunstfeld et al., 2004). Furthermore, we investigated the
effects of a targeted delivery of L19-derivatives to sites of
inflammation as we wanted to find out whether monoclonal
antibodies can be used for the selective delivery of active
molecules to sites of psoriasis. It is important to see whether
antibody-based vascular targeting strategies, similar to those
currently employed for cancer therapy, could be used for the
treatment of chronic inflammatory conditions. Two deriva-
tives of the L19 antibody (‘‘L19-IL2’’, a fusion protein with
human IL2 (Carnemolla et al., 2002; Menrad and Menssen,
2005) and ‘‘131I-SIP(L19)’’, a radioiodinated derivative of the
L19 antibody in mini-antibody format (Borsi et al., 2002;
Berndorff et al., 2005)) are currently in clinical trials for the
therapy of cancer. Furthermore, two L19-based fusion
proteins with human tumor necrosis factor alpha and human
IL12 are expected to enter clinical trials in the very near
future (Halin et al., 2002; Borsi et al., 2003). It is important to
learn about the safety profiles of L19-based drugs in
angiogenesis-related diseases, as these may be present in
polymorbid patients.
RESULTS
EDB is expressed in human lesional psoriatic skin
Expression of EDB-containing fibronectin was investigated in
human psoriatic skin specimens and in healthy skin by
immunohistochemistry using the L19 antibody. EDB-fibro-
nectin was detected surrounding dermal blood vessels and
also at the dermal–epidermal junction in psoriatic skin
sections (Figure 1a), whereas no staining was observed in
healthy skin of the same patient (Figure 1b). Similarly, EDB
was also found to be strongly expressed in the chronically
inflamed ear skin of VEGF-A transgenic mice after oxazolone-
induced delayed-type hypersensitivity reaction (Kunstfeld
et al., 2004) (Figure 1c) but not in the uninflamed ear skin
(Figure 1d). This pattern of EDB expression in psoriatic lesions
(but not in healthy skin and tissues) suggests that EDB could
serve as a target for the selective delivery of bioactive
compounds to sites of psoriasis in vivo.
The anti-EDB antibody L19 selectively accumulates in
chronically inflamed skin
The in vivo targeting performance of the anti-EDB antibody
L19 in the small immune protein format (SIP(L19); (Borsi
et al., 2002)) was analyzed in a mouse model of chronic skin
inflammation by intravenous injection of the antibody
labeled either with 125I or with the fluorophore Cy3. Figure
2a shows the results of a biodistribution study with
radiolabeled SIP(L19) in VEGF-A transgenic mice. Animals
were killed 24 hours after injection of the 125I labeled
antibody (5 mg; 7 mCi/mouse); organs were then weighed
and counted. The highest antibody uptake (5.7% ID/g) was
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Figure 1. Immunohistochemistry with an L19 antibody fragment reveals
EDB expression in human and murine psoriatic skin. (a) Expression of EDB-
fibronectin is detected at the epidermal–dermal junction and around some
vascular structures (b) but is not present in the healthy skin of the same
patient. (c) A positive staining for EDB in the hyperplastic, delayed-type
hypersensitivity-induced chronic-inflammatory lesions of the right ear in a
VEGF-transgenic mouse, (d) whereas no staining was observed in the left,
non-inflamed ear of the same animal. Bar¼ 50mm.
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Figure 2. Biodistribution of 125I-labeled SIP(L19) in psoriatic mice shows
selective accumulation of the antibody in the inflamed ear skin. (a) SIP(L19)
was labeled with 125I was injected intravenously into psoriatic mice. Twenty-
four hours after injection mice were killed and organs and ears were weighed
and counted. The antibody preferentially accumulated in the inflamed ear,
compared to normal organs. (b) An autoradiographic image of the ears
24 hours after antibody injection (n¼4).
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observed in the right (inflamed) ear. An increased antibody
uptake was also observed in the non-sensitized ear skin and
in the body skin, compatible with the VEGF overexpression at
these sites (Kunstfeld et al., 2004). By contrast, antibody
levels in blood and in normal organs were substantially lower
at this time point. An autoradiographic analysis (Figure 2b)
confirmed a higher uptake of the radioactive antibody in the
right ear.
In order to study the antibody distribution at the
microscopic level, mice were injected with 70 mg of Cy3-
labeled SIP(L19) or comparable amounts of the Cy3-labeled
antibody SIP(HyHEL10), which does not recognize any
antigen in the mouse and can thus be used as negative
control (Smith-Gill et al., 1984). An ex vivo fluorescence
microscopic analysis of cryosections of the ears 24 hours after
injection of SIP(L19) showed a strong fluorescent staining
pattern in vascular structures of both ears. By contrast, no
preferential antibody uptake was observed with SIP(HyHEL-
10), confirming the ability of the L19 antibody to selectively
target neovascular structures (Figure 3).
The L19 antibody can be used to deliver bioactive molecules to
sites of chronic skin inflammation
We had previously shown that the targeted delivery of the
photosensitizer bis(triethanolamine) Sn(IV) chlorin e6
(SnChe6) coupled to the L19 antibody, followed by irradiation
with red light, mediated a complete and selective occlusion
of new blood vessels in a rabbit model of ocular angiogenesis
(Birchler et al., 1999) and in subcutaneous tumors grafted in
mice (Fabbrini et al., 2006), thus conferring a therapeutic
benefit. In order to evaluate whether the targeted delivery of
SnChe6 to sites of chronic inflammation could decrease ear
inflammation, VEGF-tg mice sensitized with oxazolone at the
right ear were injected (3 in 1 week intervals) with 160mg
of SIP(L19)-SnChe6 conjugate and irradiated 24 hours after
injection (150 J/cm2 at 630 nm). In the control group, mice
did not receive the antibody conjugate, but were irradiated in
identical conditions as mice of the treatment group. As
illustrated in Figure 4, the animals treated with SIP(L19)-
SnChe6 showed a substantial reddening and swelling of the
inflamed ears at the end of the therapeutic cycle, whereas the
inflammation in the ears in control mice had gone back to
baseline (i.e., comparable to the one of the non-inflamed
ears). Thus, the L19-mediated targeted delivery of a photo-
sensitizer enhanced inflammation in this mouse model.
Motivated by the fact that L19-based antibody-cytokine
fusion proteins have exhibited curative effects in mouse
models of cancer (Carnemolla et al., 2002; Halin et al., 2002,
2003; Borsi et al., 2003; Ebbinghaus et al., 2005) and are
currently investigated in clinical trials in the oncology setting
(Menrad and Menssen, 2005), we studied the therapeutic
effect of L19 fusions with two proinflammatory cytokines
(L19-IL2 and L19-IL12) and one anti-inflammatory cytokine
(L19-IL10) in the VEGF-tg mouse model of chronic skin
inflammation. The proinflammatory fusion protein L19-IL2
markedly increased the swelling of the inflamed ear and also
led to edema formation in the previously not affected ear
(Figure 5). However, the increased ear swelling only persisted
for several days. The targeted delivery of IL12, at a dose,
which is therapeutic in mouse models of cancer did not affect
the degree of ear inflammation. Similarly, the fusion protein
L19-IL10 did not display a therapeutic effect in this mouse
model (Figure 5), which contrasts with the prominent
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Figure 3. Ex vivo fluorescence microscopy analysis of ear sections from
VEGF-transgenic mice reveals a selective accumulation of SIP(L19)
compared with an irrelevant antibody. Mice were injected with Cy3-labeled
SIP(L19) or SIP(HyHEL10), an antibody of irrelevant specificity in the mouse,
24 hours before euthanasia. (a and b) Accumulation of SIP(L19)-Cy3
surrounding blood vessels in the chronically inflamed ear skin of VEGF-
transgenic mice, whereas (c and d) no preferential antibody uptake was
observed with SIP(HyHEL10)-Cy3. Bar¼ 100 mm.
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Figure 4. Photodynamic therapy with L19-SnChe6 does not lead to a
therapeutic effect in psoriatic mice. Psoriatic mice were injected (3 in 1
week intervals) with 160 mm of L19-SnChe6 conjugate and irradiated 24 hours
after injection. Mice were photographed 1 day after the third irradiation.
Increased swelling and reddening of inflamed ears (indicated by the arrows in
(a) can be observed in mice treated with the L19-SnChe6, whereas (b) the ear
swelling in psoriatic mice that had only been irradiated without previous
injection of the antibody-photosensitizer conjugate had gone back to
baseline.
www.jidonline.org 883
E Trachsel et al.
Antibodies for Targeting of Psoriasis
therapeutic effects observed in the collagen-induced mouse
model of arthritis (Trachsel et al., submitted).
DISCUSSION
We have shown that the EDB domain of fibronectin (a marker
of angiogenesis and of tissue remodeling which is virtually
undetectable in normal adult tissues) is expressed in human
psoriasis as well as in a mouse model of chronic skin
inflammation. The high-affinity human antibody L19, specific
to EDB, is able to selectively localize at sites of inflammation
in a VEGF-transgenic mouse model, thus opening new
biomedical intervention modalities, similar to the ones
currently in clinical trials for therapy of cancer.
The L19-mediated targeted delivery of a photosensitizer to
the site of inflammation, followed by irradiation with red
light, led to increased reddening and swelling of the inflamed
ear. This finding confirms that the L19 antibody selectively
delivered bioactive molecules to sites of inflammation, but
was surprising as photodynamic therapy with psoralen plus
ultraviolet light A is a well-established treatment for psoriasis.
The successful use of L19 for the immunophotodynamic
therapy of ocular angiogenesis (Birchler et al., 1999) and of
superficial tumors (Fabbrini et al., 2006) contrasts with the
results observed in the VEGF-transgenic mouse model of
chronic skin inflammation, where the localized singlet
oxygen production appears to cause a burst of inflammation
mediators. It remains to be seen whether these findings are
confined to the animal model used in our study, or whether
they would hold true also for the human pathology.
Similarly, the observation that L19-IL2 selectively en-
hanced ear inflammation in VEGF-transgenic mice has
several implications. The experiments clearly show that the
L19 antibody can be used to deliver cytokines at sites of
chronic inflammation. As expected, IL2 triggered a proin-
flammatory reaction, which persisted for several days but
resolved spontaneously. This information is important, in
light of the fact that L19-IL2 is being investigated in clinical
trials in patients with cancer. At some stage, it is likely that
polymorbid patients with cancer and psoriasis may be
considered for L19-IL2-based therapy.
L19-IL12 shows a therapeutic profile similar to L19-IL2 in
tumor-bearing mice (Halin et al., 2002, 2003; Gafner et al.,
2006). The observation that this fusion protein did not
enhance inflammation represents a distinguishing safety
aspect, with important implications for the clinical investiga-
tion of this fusion protein in patients with cancer. In contrast,
the absence of a therapeutic effect of L19-IL10 in our
experimental setting was unexpected, considering that
recombinant IL10 (Tenovils) has been tested in clinical trials
for several types of chronic inflammatory disorders, including
psoriasis. L19-IL10 provides a considerable therapeutic
benefit in the collagen-induced mouse model of rheumatoid
arthritis, superior to the one of untargeted IL10 (Trachsel
et al., submitted). The lack of therapeutic activity of L19-IL10
in our mouse model of chronic skin inflammation may be
attributed to the constant expression of VEGF, which may
counter-balance the anti-inflammatory reactions induced
by IL10.
In summary, our study shows that the L19 antibody can be
used for targeting bioactive molecules at sites of chronic skin
inflammation, but underlines the need to identify bioactive
molecules which can be fused to antibodies and which
display a therapeutic effect as a result of their preferential
accumulation in psoriatic lesions and other sites of inflam-
mation. A number of cytokines (e.g., IL4) could in principle
be considered. Additionally, we could envisage the use of
L19-drug conjugates with cleavable linkers or antibody-
dependent prodrug therapy strategies, in order to selectively
increase drug concentrations at sites of psoriasis (Bagshawe
et al., 2004). The use of antibody-drug conjugates is possibly
easier to implement, but will require potent drugs which
match the high molecular weight of the antibody, as well as
suitable release mechanisms.
MATERIALS AND METHODS
Induction of delayed-type hypersensitivity reactions
Delayed-type hypersensitivity reactions were induced in the ear skin
of 8-week-old female FVB mice that overexpress VEGF-A164 in the
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Figure 5. Effects of antibody-cytokine fusion proteins on chronic, psoriasis-
like skin inflammation. Psoriatic mice were injected intravenously with
different cytokine-fusion proteins. The plots show the (a) swelling of the right
ear and of the (b) unsensitized left ear at different time points, as a result of the
treatment with antibody-cytokine fusion proteins. Open squares: L19-IL2;
open triangles, dashed line: L19-IL12; black circles, dashed line: L19-IL10;
crosses: saline control.
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epidermis under control of the human keratin 14 promoter (Detmar
et al., 1998) as described previously (Xia et al., 2003; Kunstfeld
et al., 2004). For all studies, heterozygous VEGF transgenic mice
were used at an age of 8 weeks, and there were no pre-existing
inflammatory lesions at that age. Mice were sensitized by topical
application of a 2% oxazolone (4-ethoxymethylene-2-phenyl-2-
oxazoline-5-one; Sigma, St Louis, MO) solution in acetone/olive oil
(4:1 vol/vol) to the shaved abdomen (50 ml) and to each paw (5ml).
Five days after sensitization (¼ day 0), the right ears were challenged
by topical application of 20 ml of a 1% oxazolone solution, whereas
the left ears were treated with the vehicle alone. The ear thickness
and extent of swelling was measured using the ear swelling test (Gad
et al., 1986).
Immunohistochemistry
Frozen sections of human and murine psoriatic and healthy skin
were fixed in ice-cold acetone and were stained for EDB. For murine
specimens the L19 antibody was used in the mini-antibody format
(SIP(L19)). As secondary detection antibodies we used rabbit
antihuman IgE (Dako, Denmark) followed by biotinylated antirabbit
IgG (Biospa, Italy) and streptavidin–alkaline phosphatase complex
(Biospa). For human skin sections the L19 antibody was used in the
IgG format (IgG(L19)), followed by a rabbit anti-mouse IgG (Dako)
and by APAAP Mouse Monoclonal (Dako). Fast Red TRSalt (Sigma,
Switzerland) was used to develop the staining. Slides were counter-
stained with hematoxylin, mounted with Glycergel mounting
medium (Dako) and analyzed with a Axiovert S100 TV microscope
(Zeiss, Switzerland).
Biodistribution experiments
The in vivo targeting performance of SIP(L19) in psoriatic mice was
evaluated by biodistribution analysis as described previously (Tarli
et al., 1999; Borsi et al., 2002). Briefly, purified SIP(L19) was
radioiodinated and the labeled protein (5 mg, 7mCi) was injected into
the tail vein of psoriatic mice (n¼ 4). Mice were killed 24 hours after
injection.
Organs and ears were weighed and radioactivity was counted
with a Cobra g counter (Packard, Meriden, CT). Radioactivity
content of representative organs was expressed as the percentage of
the injected dose per gram of tissue (% ID/g). Ears were further
exposed overnight and read with a phosphor-imager (BAS-5000,
Fujifilm, Stamfort, CT).
Ex vivo fluorescence experiments
SIP(L19) and SIP(HyHEL10) were prepared as described previously
(Borsi et al., 2002; Fabbrini et al., 2006). The antibodies were
labeled with Cy3-NHS ester (Amersham Pharmacia, Du¨bendorf,
Switzerland) following the manufacturer’s recommendation. The
final labeling antibody:dye ratio was 1:2.7 for SIP(L19) and 1:3.3 for
SIP(HyHEL10), respectively. Seventy micrograms of either antibody
conjugate were intravenously injected in psoriatic mice. Twenty-
four hours after injection, the animals were killed and the ears were
embedded in cryo-embedding compound (Microm, Germany),
frozen on dry ice and 70% ethanol and stored at 801C. Sections
of 8 mm were cut, fixed with 4% paraformaldehyde for 15 minutes at
room temperature, counterstained with Hoechst 33342, mounted
with glycergel (Dako), and analyzed with a AxioScop
2MOTþ (Zeiss, Switzerland).
Photodynamic therapy
Immunoconjugates of SIP(L19)-SnChe6 were prepared as described
previously (Fabbrini et al., 2006). The labeling ratio of photosensi-
tizer to anibody was 2.1/1. Mice were injected three times (on days
0, 7, and 14) with 160mg/mouse of SIP(L19)-SnChe6 or with
phosphate-buffered saline. Twenty-four hours after each injection
mice were anesthesized with a single intraperitoneal injection of
avertin (0.5mg per 10 mg body weight 2,2,2-tribromoethanol in
2.5% tert-amyl alcohol; Sigma, St Louis, MO), immediately before
light exposure and irradiated with an argon-pumped dye laser at
630 nm. The illuminated area was about 2 cm2 and the total dose of
light delivered was about 150 J/cm2, as measured with an SL818
photodetector (Newport Corporation, Irvine, CA). Experiments were
performed in agreement with US regulations. At the end of the
experiment mice were photographed and then killed.
Targeted delivery of cytokines to psoriatic lesions
Immunocytokines L19-IL2, L19-IL12, and L19-IL10 were prepared
as described previously (Carnemolla et al., 2002; Gafner et al.,
2006; Trachsel et al., submitted). On day 4 after challenge with
oxazolone, mice were divided in groups of five animals and therapy
was started. Mice were injected intravenously (i.v.) in the lateral
tail vein with saline, L19-IL2, L19-IL12, or L19-IL10 diluted in a
volume of 200ml of saline. The cumulative doses for the fusion
proteins were: 72 mg of L19-IL2; 160mg of L19-IL12; 300 mg of
L19-IL10 per mouse, respectively. Ear thickness was measured
daily until day 11 and then twice weekly until day 39. Experiments
were performed in agreement with Swiss regulations and under
a project license granted by the Veterina¨ramt des Kantons Zu¨rich
(180/2004).
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